Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Danish pharma giant Novo Nordisk on Tuesday launched its blockbuster weight loss drug Wegovy as a once-a-week injection in ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.